Cargando…
Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication
BACKGROUND: Children with attention-deficit/hyperactivity disorder (ADHD) show a marked temporal variability in their display of symptoms and neuropsychological performance. This could be explained in terms of an impaired glial supply of energy to support neuronal activity. METHOD: We pursued one te...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889842/ https://www.ncbi.nlm.nih.gov/pubmed/20509936 http://dx.doi.org/10.1186/1744-9081-6-29 |
_version_ | 1782182722081390592 |
---|---|
author | Oades, Robert D Dauvermann, Maria R Schimmelmann, Benno G Schwarz, Markus J Myint, Aye-Mu |
author_facet | Oades, Robert D Dauvermann, Maria R Schimmelmann, Benno G Schwarz, Markus J Myint, Aye-Mu |
author_sort | Oades, Robert D |
collection | PubMed |
description | BACKGROUND: Children with attention-deficit/hyperactivity disorder (ADHD) show a marked temporal variability in their display of symptoms and neuropsychological performance. This could be explained in terms of an impaired glial supply of energy to support neuronal activity. METHOD: We pursued one test of the idea with measures of a neurotrophin reflecting glial integrity (S100B) and the influences of 8 cytokines on the metabolism of amino-acids, and of tryptophan/kynurenine to neuroprotective or potentially toxic products that could modulate glial function. Serum samples from 21 medication-naïve children with ADHD, 21 typically-developing controls, 14 medicated children with ADHD and 7 healthy siblings were analysed in this preliminary exploration of group differences and associations. RESULTS: There were no marked group differences in levels of S100B, no major imbalance in the ratios of pro- to anti-inflammatory interleukins nor in the metabolism of kynurenine to toxic metabolites in ADHD. However, four trends are described that may be worthy of closer examination in a more extensive study. First, S100B levels tended to be lower in ADHD children that did not show oppositional/conduct problems. Second, in medicated children raised interleukin levels showed a trend to normalisation. Third, while across all children the sensitivity to allergy reflected increased levels of IL-16 and IL-10, the latter showed a significant inverse relationship to measures of S100B in the ADHD group. Fourthly, against expectations healthy controls tended to show higher levels of toxic 3-hydroxykynurenine (3 HK) than those with ADHD. CONCLUSIONS: Thus, there were no clear signs (S100B) that the glial functions were compromised in ADHD. However, other markers of glial function require examination. Nonetheless there is preliminary evidence that a minor imbalance of the immunological system was improved on medication. Finally, if lower levels of the potentially toxic 3 HK in ADHD children were confirmed this could reflect a reduction of normal pruning processes in the brain that would be consistent with delayed maturation (supported here by associations with amino-acid metabolism) and a reduced metabolic source of energy. |
format | Text |
id | pubmed-2889842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28898422010-06-23 Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication Oades, Robert D Dauvermann, Maria R Schimmelmann, Benno G Schwarz, Markus J Myint, Aye-Mu Behav Brain Funct Research BACKGROUND: Children with attention-deficit/hyperactivity disorder (ADHD) show a marked temporal variability in their display of symptoms and neuropsychological performance. This could be explained in terms of an impaired glial supply of energy to support neuronal activity. METHOD: We pursued one test of the idea with measures of a neurotrophin reflecting glial integrity (S100B) and the influences of 8 cytokines on the metabolism of amino-acids, and of tryptophan/kynurenine to neuroprotective or potentially toxic products that could modulate glial function. Serum samples from 21 medication-naïve children with ADHD, 21 typically-developing controls, 14 medicated children with ADHD and 7 healthy siblings were analysed in this preliminary exploration of group differences and associations. RESULTS: There were no marked group differences in levels of S100B, no major imbalance in the ratios of pro- to anti-inflammatory interleukins nor in the metabolism of kynurenine to toxic metabolites in ADHD. However, four trends are described that may be worthy of closer examination in a more extensive study. First, S100B levels tended to be lower in ADHD children that did not show oppositional/conduct problems. Second, in medicated children raised interleukin levels showed a trend to normalisation. Third, while across all children the sensitivity to allergy reflected increased levels of IL-16 and IL-10, the latter showed a significant inverse relationship to measures of S100B in the ADHD group. Fourthly, against expectations healthy controls tended to show higher levels of toxic 3-hydroxykynurenine (3 HK) than those with ADHD. CONCLUSIONS: Thus, there were no clear signs (S100B) that the glial functions were compromised in ADHD. However, other markers of glial function require examination. Nonetheless there is preliminary evidence that a minor imbalance of the immunological system was improved on medication. Finally, if lower levels of the potentially toxic 3 HK in ADHD children were confirmed this could reflect a reduction of normal pruning processes in the brain that would be consistent with delayed maturation (supported here by associations with amino-acid metabolism) and a reduced metabolic source of energy. BioMed Central 2010-05-28 /pmc/articles/PMC2889842/ /pubmed/20509936 http://dx.doi.org/10.1186/1744-9081-6-29 Text en Copyright ©2010 Oades et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Oades, Robert D Dauvermann, Maria R Schimmelmann, Benno G Schwarz, Markus J Myint, Aye-Mu Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication |
title | Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication |
title_full | Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication |
title_fullStr | Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication |
title_full_unstemmed | Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication |
title_short | Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism - effects of medication |
title_sort | attention-deficit hyperactivity disorder (adhd) and glial integrity: s100b, cytokines and kynurenine metabolism - effects of medication |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889842/ https://www.ncbi.nlm.nih.gov/pubmed/20509936 http://dx.doi.org/10.1186/1744-9081-6-29 |
work_keys_str_mv | AT oadesrobertd attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication AT dauvermannmariar attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication AT schimmelmannbennog attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication AT schwarzmarkusj attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication AT myintayemu attentiondeficithyperactivitydisorderadhdandglialintegritys100bcytokinesandkynureninemetabolismeffectsofmedication |